PTGS2 and prostate cancer: Rats with prostate cancer were characterized by a significant elevation in (i) cancer growth rate-limiting enzymes, 5-α reductase and Na+/K+ATPase activities, (ii) cancer biomarkers, prostate-specific antigen (PSA) and carcinoembryonic antigen (CEA) levels, and (iii) inflammation biomarkers, COX-2 production compared with the corresponding markers in the negative control.